menu
    • menu
    [{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0.64000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.64000000000000001,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Bayer AG"}]

    Find Clinical Drug Pipeline Developments & Deals for Dorzagliatin

    Menu

    Dorzagliatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Hua Medicine

    China arrow
    Conjugates Summit
    Not Confirmed

    Hua Medicine

    China arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dorzagliatin

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Bayer AG

    Deal Size : $635.8 million

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Bayer and Hua Medicine Announce Commercialization Agreement

    Details : Hua Medicine shall be responsible for clinical development, registration, product supply and distribution of dorzagliatin, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in Ch...

    Product Name : HMS5552

    Product Type : Small molecule

    Upfront Cash : $43.3 milllion

    August 17, 2020

    Lead Product(s) : Dorzagliatin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Bayer AG

    Deal Size : $635.8 million

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Hua Medicine

    China arrow
    Conjugates Summit
    Not Confirmed

    Hua Medicine

    China arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dorzagliatin,Metformin

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliat...

    Details : All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.

    Product Name : HMS5552

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    July 01, 2020

    Lead Product(s) : Dorzagliatin,Metformin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Hua Medicine

    China arrow
    Next-Gen Conjugates
    Not Confirmed

    Hua Medicine

    China arrow
    Next-Gen Conjugates
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dorzagliatin,Empagliflozin

    Therapeutic Area : Endocrinology

    Study Phase : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 ...

    Details : The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 26, 2020

    Lead Product(s) : Dorzagliatin,Empagliflozin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth